Please login to the form below

Not currently logged in
Email:
Password:

Hutchison China Medipharma signs research agreement with Eli Lilly

China-headquartered pharmaceutical company, Hutchison China Meditech, has revealed that its Hutchison MediPharma (HMPL) unit agreed a research collaboration with US-based Eli Lilly to co-develop oncology and anti-inflammatory medicines.

China-headquartered pharmaceutical company, Hutchison China Meditech, has revealed that its Hutchison MediPharma (HMPL) unit agreed a research collaboration with US-based Eli Lilly to co-develop oncology and anti-inflammatory medicines.

Hutchison will be awarded milestone payments of between USD 20m and USD 29m according to the type of clinical candidate. The company will also receive an upfront fee, annual R&D support costs, as well as also potential royalties.

Per the agreement, Hutchison will take responsibility for initial R&D, while Eli Lilly will offer technological advice and clinical trial expertise as the project develops.

Hutchison said that the research will be based in China to reduce overall costs.

In July 2007, Lilly revealed that the Oncologic Drugs Advisory Committee of the FDA had voted to recommend approval of its osteoporosis drug Evista (raloxifene) for a new use to reduce invasive breast cancer risk in post-menopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.

Lilly's cancer pipeline includes enzastaurin for brain cancer, which it intends to submit to the FDA in 2008, as well as arzoxifene for osteoporosis and prevention of breast cancer for submission in 2009.

HMPL currently has clinical programmes in preclinical and discovery stages to study its leading oncology candidate, a radio sensitiser, in multiple types of cancers, including non-small cell lung cancer (NSCLC) and head and neck cancer. The company's discovery research is focused on specific oncological and haematological targets with a full panel of in-vitro and in-vivo assays.

2nd September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics